Phosphoribosylglycinamide Formyltransferase

19  relevant articles (0 outcomes, 2 trials/studies) found for this Bio-Agent

2-Amino-N-Ribosylacetamide 5'-Phosphate Transformylase; 5'-Phosphoribosylglycinamide Transformylase; GAR Formyltransferase; GAR Transformylase; GARTFase; Glycinamide Ribonucleotide Transformylase; Glycinamideribotide Transformylase; 2 Amino N Ribosylacetamide 5' Phosphate Transformylase; 5' Phosphoribosylglycinamide Transformylase; 5'-Phosphate Transformylase, 2-Amino-N-Ribosylacetamide; Formyltransferase, GAR; Formyltransferase, Phosphoribosylglycinamide; Ribonucleotide Transformylase, Glycinamide; Transformylase, 2-Amino-N-Ribosylacetamide 5'-Phosphate; Transformylase, 5'-Phosphoribosylglycinamide; Transformylase, GAR; Transformylase, Glycinamide Ribonucleotide; Transformylase, Glycinamideribotide

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 01/09/2007 - "Human glycinamide ribonucleotide transformylase (GART) (EC 2.1.2.2) is a validated target for cancer chemotherapy, but mechanistic studies of this therapeutically important enzyme are limited" 01/01/1989 - "In vivo studies with 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), an inhibitor of glycinamide ribonucleotide transformylase, indicate that at doses ranging from 2.5 to 10 mg/kg, it prolongs the survival of mice implanted with L1210 tumors" 06/01/1994 - "GAR transformylase activity was higher in colon 38 tumor than in liver, but a kinetic analysis on the purified enzyme showed no differences in Ki values for DDATHF or Km values for the folate substrate" 12/14/1993 - "These data show that even for tumor cells with severely impaired antifolate transport, the extensive conversion of DDATHF to polyglutamyl forms required for GAR transformylase inhibition preserves high levels of antitumor activity." 01/01/1998 - "PURPOSE: The whole-body autoradiographic distribution of two radiolabeled antifolate inhibitors of GAR formyltransferase, lometrexol and LY309887, were compared in tumor-bearing mice maintained on standard diet (SD) and a low-folate diet (LFD) in order to determine the total amounts of drug that accumulated in blood, tumor, liver and kidney" Order ALL the reference details at left...
2.	Leukemia 01/01/1991 - "The results suggest that GAR transformylase is a target for a series of compounds whose structures resemble that of tetrahydrofolate and indicate that the inhibition of GAR transformylase by these compounds is sufficient to induce the maturation of HL-60 leukemia cells." 01/01/1993 - "5,10-Dideazatetrahydrofolic acid (DDATHF) is an inhibitor of glycinamide ribonucleotide transformylase, the first of two tetrahydrofolate requiring enzymes in the de novo purine nucleotide biosynthetic pathway, and is a potent inducer of the maturation of HL-60 promyelocytic leukemia cells" 01/15/2002 - "We determined the mechanisms of resistance of human CCRF-CEM leukemia cells to methotrexate (MTX) vs. those to six novel antifolates: the polyglutamatable thymidylate synthase (TS) inhibitors ZD1694, multitargeted antifolate, pemetrexed, ALIMTA (MTA) and GW1843U89, the non-polyglutamatable inhibitors of TS, ZD9331, and dihydrofolate reductase, PT523, as well as DDATHF, a polyglutamatable glycinamide ribonucleotide transformylase inhibitor" Order ALL the reference details at left...
3.	Lymphoma (Lymphomas) 10/01/1986 - "This quinazoline folate analogue showed no activity as a substrate for the folate-requiring de novo purine biosynthetic enzyme glycinamide ribonucleotide transformylase isolated from the murine lymphoma cell line L5178Y, but proved to be a potent competitive inhibitor, Ki = 1.3 microM, of the purified enzyme." 03/12/1985 - "Glycinamide ribonucleotide transformylase, the first of the two formyl group transferases of de novo purine biosynthesis requiring 10-formyltetrahydrofolate, has been purified 1500-fold, nearly to homogeneity, from the murine lymphoma cell line L5178Y" Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 02/01/1996 - "Lometrexol (5,10-dideazatetrahydrofolic acid; DDATHF), is a specific inhibitor of glycinamideribonucleosyl (GAR) transformylase with anti-tumour activity in murine and human carcinomas" 03/15/1994 - "We have investigated the potential of glycineamide ribonucleotide transformylase (GAR TFase) inhibitors to produce regressions in multiple preclinical models of colon carcinoma" Order ALL the reference details at left...
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/1994 - "The mechanism of action of TNP-351 was evaluated using some methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as partially purified enzymes folylpolyglutamate synthetase (FPGS), aminoimidazolecarboxamide ribonucleotide transformylase (AICARTFase), and glycinamide ribonucleotide transformylase (GARTFase) from parent CCRF-CEM cells" Order ALL the reference details at left...

Related Drugs and Biologics

1.	lometrexol
2.	Methotrexate (Mexate)
3.	Thymidylate Synthase
4.	purine
5.	folylpolyglutamate synthetase
6.	Phosphoribosylglycinamide Formyltransferase
7.	Enzymes
8.	5,6,7,8-tetrahydrofolic acid (tetrahydrofolate)
9.	Phosphoribosylaminoimidazolecarboxamide Formyltransferase
10.	Transferases

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)